Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 05 February 2018

Indication(s)

Inhixa is indicated in adults for:
• Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
• Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
• Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
• Acute coronary syndrome:
- Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
- Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Load more

Related Content

Journal articles

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Background: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.

Added 7 months ago

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.

Added 7 months ago

Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.

Aim: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome...

Added 7 months ago

Rivaroxaban in patients with a recent acute coronary syndrome.

Background: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve...

Added 7 months ago

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients

Venous thromboembolism (VTE) is a potential cause of morbidity and mortality in patients after major orthopaedic surgery. Based on the...

Added 3 years ago

Load more

View all 12690 Journal articles items
Guidelines

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

VTE is a condition in which a blood clot (thrombus) forms in a vein. It most commonly occurs in the...

Added 8 years ago

Guideline on aspects of cancer-related venous thrombosis

This guideline reviews the indication for warfarin, duration or treatment for patients with a PE and/or lower limb DVT, the initiation of treatment, the management of peri-operative anticoagulation, the management of patients who are bleeding or...

Added 2 years ago

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

This guideline covers the diagnosis and management of venous thromboembolic diseases in adults (aged 18 and over), and the role of thrombophilia testing.

Added 5 years ago

Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease

This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction.

Added 4 years ago

Load more

View all 1410 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/004264
Orphan designation No
Date First Approved 15-09-2016
Type Medicinal product subject to medical prescription
Marketing authorisation holder Techdow Europe AB